This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Río, J Articles by Montalban, X Search for Related Content PubMed PubMed Citation Articles by Río, J Articles by Montalban, X Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information MRI Scans Social Bookmarking                   What's this?

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain, jrio{at}vhebron.net

À Rovira

Unitat de Ressonància Magnètica (IDI), Hospital Universitario Vall d’Hebron, Barcelona, Spain

M Tintoré

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

E Huerga

Unitat de Ressonància Magnètica (IDI), Hospital Universitario Vall d’Hebron, Barcelona, Spain

C Nos

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

N Tellez

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

C Tur

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

M Comabella

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

X Montalban

Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d’Hebron, Barcelona, Spain

Objective

Our objective in this study is to evaluate whether brain magnetic resonance imaging (MRI) performed at interferon-beta (IFN-β) onset and after 12 months allow us to identify relapsing–remitting multiple sclerosis (RRMS) patients with a disability increase in the first 2 years of therapy.

Methods

This is a prospective and longitudinal study of patients with RRMS treated with IFN-β. All patients included underwent brain MRI before the onset of therapy with IFN-β and 12 months after. MRI measures (T2, unenhanced T1-weighted and gadolinium-enhancing T1-weighted brain lesion load, brain parenchymal fraction) were undertaken at baseline and after 12 months. The number of active lesions (new or enlarging T2 plus gadolinium-enhancing brain lesions) was also assessed on the 12 months MRI scan. Expanded Disability Status Scale (EDSS) was scored every 3 months. We defined an increase in disability as an increase of at least 1 EDSS point confirmed and sustained during the first 2 years of therapy with IFN-β. Regression analysis was performed in order to identify MRI variables of response.

Results

We included 152 patients who were followed-up for at least 2 years. After 2 years of therapy, 24 patients (16%) had an increase in disability. The logistic regression model showed that active lesions in the scan performed at 12 months were the most important factor related with the increase of disability after 2 years of therapy (odds ratio 8.3, 95% confidence interval 3.1–21.9; p < 0.0001).

Conclusions

In RRMS patients treated with IFN-β the MRI changes occurring during the first year may have a prognostic value for identifying patients with a confirmed increase of disability after 2 years of therapy.

Key Words: beta-interferon • disease modifying therapies • multiple sclerosis • MRI

Multiple Sclerosis, Vol. 14, No. 4, 479-484 (2008)
DOI: 10.1177/1352458507085555


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga, C Nos, M Comabella, X Aymerich, and X Montalban Measures in the first year of therapy predict the response to interferon {beta} in MS Multiple Sclerosis, July 1, 2009; 15(7): 848 - 853. [Abstract] [PDF]